Adjuvant chemotherapy for ctDNA positive patients- Randomized phase II study of comparing FOLFOX6 with FOLFOXIRI+Bevaxcizumab
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/97707
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: At enrollment, each subject will be assigned to one of the following treatment groups
mFOLFOXIRI + BV therapy every 2 weeks for up to 8 cycles, followed by maintenance therapy for a total of up to 12 cycles.
mFOLFOX6 therapy every 2 weeks for up to12 cycles.;C410216, C509829, D000068258;mFOLFOX6, mFOLFOXIRI, bevacizumab, mFOLFOX6
Primary outcome(s): the percentage of ctDNA negative conversion
Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
创建时间：
2023-01-15
